Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

NCT07030257 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Malignancies
Colorectal Carcinoma
Small Cell Lung Cancer ( SCLC )
Head and Neck (HNSCC)
Bladder Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer, Advanced or Metastatic

Interventions

DRUG: CP-383

Sponsor

Tasca Therapeutics